Current and Future Directions in the Treatment of Colorectal Cancer
This activity contains:
- CME/CPE/CNE-Certified Live Grand Rounds and Webinars
- Downloadable Slide Deck with Facilitator's Guide (a non-certified educational resource)
The goal of this activity is provide the latest information on new and emerging therapies for the treatment of colorectal cancer.
The advent of several approved targeted therapies for the treatment of colorectal cancer (CRC) has improved patient outcomes. However, due to the development of drug resistance, disease ultimately relapses and the prognosis of progressive disease is very poor. Clinicians who manage CRC must be up to date on these therapies to optimize the care they provide. In particular, they may benefit from education on biomarker screening of disease, mutation analysis to personalize treatment, optimal sequencing, individualization of treatment plan, and the elucidation of cross-resistance mechanisms. Moreover, the rapid pace of the development of new therapies in this field has necessitated provider education on the identification of patients who may benefit from these therapies.
- Overview of colorectal cancer
- Individualization of treatment based on disease characteristics
- Emerging therapies for advanced/metastatic colorectal cancer
- Mechanisms of drug resistance to therapies in colorectal cancer
- Clinical patient case challenges
This activity is intended for physicians, advanced practice registered nurses, nurses, pharmacists, and other healthcare professionals who manage patients with colorectal cancer.
At the conclusion of this activity, participants should be better able to:
- Summarize best practices for biomarker screening and mutational analysis in colorectal cancer that guide the selection of therapeutic interventions.
- Identify best practices for the individualization of treatment strategies for colorectal cancer based on practice guidelines and emerging clinical evidence.
- Describe novel therapies for the treatment of metastatic colorectal cancer based on emerging clinical data from trials.
- Identify effective strategies for the management of treatment related side effects with colorectal cancer therapies.
- Describe resistance mechanisms that can reduce response to treatment in colorectal cancer, and identify combination therapies that may circumvent drug resistance in patients.
Cathy Eng. MD, FACP
|Bert H. O’Neil, MD|
Director, Phase I & GI Oncology Programs
Indiana University Simon Cancer Center
Steven J. Cohen, MD
|Arvind Dasari, MD|
Assistant Professor, GI Medical Oncology
The University of Texas MD Anderson Cancer Center
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation for Physicians
AXIS Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit Designation for Pharmacists
This application-based activity is approved for 1.0 contact hour of continuing pharmacy education credit (UAN 0592-0000-17-003-L01-P).
Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.
For advance practice nurses, this activity has 0.25 contact hours of pharmacotherapy content.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
California Board of Registered Nursing
AXIS is approved by the California Board of Registered Nursing, Provider Number 16702, for 1.0 contact hour.
Iowa Board of Nursing
AXIS is Iowa Board of Nursing Approved Provider Number 371, for 1.0 contact hour.
Disclosure of Conflicts of Interest
AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
|Name of Faculty or Presenter||Reported Financial Relationship|
|Cathy Eng, MD, FACP||Cathy Eng, MD, FACP, reported a financial interest/relationship or affiliation in the form of Consultant, Genentech/Roche, Bayer Pharmaceuticals; Speakers' bureau, Genentech, Inc., Daiichi-Sankyo, Inc.,Keryx Biopharmaceuticals, Inc..|
|Bert H. O’Neil, MD||Bert H. O’Neil, MD reported a financial interest/relationship or affiliation in the form of Advisory board/consulting, AMGEN, Genentech & Bayer|
|Steven J. Cohen, MD||Steven J. Cohen, MD, reported a financial interest/relationship or affiliation in the form of consulting fee, Merck & Co., Inc.; consulting fee, Genentech, Inc.; Received income in any amount from, Merrimack Pharmaceuticals.|
|Arvind Dasari, MD||Arvind Dasari, MD reported a financial interest/relationship or affiliation in the form of consultant, Novartis Pharmaceuticals, Ipsen Pharmaceuticals, and Voluntis; received a research grant from, Novartis Pharmaceuticals, Ipsen Pharmaceuticals and Eisai Pharmaceutical.|
The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
The following AXIS planners and managers, Linda Gracie-King, MS; Ronald Viggiani, MD; Jocelyn Timko, BS; Marilyn Haas, PhD, RN, CNS, ANP-BC; and Stephanie Sutphin, PharmD hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.
This activity is supported by an educational grant from Genentech.
There is no fee for this educational activity.
This activity is provided by:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ACPE
- 1.00 ANCC
- 1.00 Attendance